QIPT vs. FLGT, INNV, CELC, EHAB, PSNL, AIRS, VMD, LFMD, SERA, and BDSX
Should you be buying Quipt Home Medical stock or one of its competitors? The main competitors of Quipt Home Medical include Fulgent Genetics (FLGT), InnovAge (INNV), Celcuity (CELC), Enhabit (EHAB), Personalis (PSNL), AirSculpt Technologies (AIRS), Viemed Healthcare (VMD), LifeMD (LFMD), Sera Prognostics (SERA), and Biodesix (BDSX). These companies are all part of the "healthcare" industry.
Quipt Home Medical vs.
Fulgent Genetics (NASDAQ:FLGT) and Quipt Home Medical (NASDAQ:QIPT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, community ranking, earnings, media sentiment and risk.
Fulgent Genetics presently has a consensus target price of $22.00, indicating a potential upside of 33.66%. Quipt Home Medical has a consensus target price of $6.25, indicating a potential upside of 146.06%. Given Quipt Home Medical's stronger consensus rating and higher probable upside, analysts clearly believe Quipt Home Medical is more favorable than Fulgent Genetics.
In the previous week, Quipt Home Medical had 15 more articles in the media than Fulgent Genetics. MarketBeat recorded 16 mentions for Quipt Home Medical and 1 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.76 beat Quipt Home Medical's score of 0.47 indicating that Fulgent Genetics is being referred to more favorably in the media.
Fulgent Genetics received 213 more outperform votes than Quipt Home Medical when rated by MarketBeat users. However, 83.78% of users gave Quipt Home Medical an outperform vote while only 60.10% of users gave Fulgent Genetics an outperform vote.
Quipt Home Medical has a net margin of -2.90% compared to Fulgent Genetics' net margin of -59.39%. Fulgent Genetics' return on equity of -1.81% beat Quipt Home Medical's return on equity.
48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 42.9% of Quipt Home Medical shares are owned by institutional investors. 31.8% of Fulgent Genetics shares are owned by company insiders. Comparatively, 13.4% of Quipt Home Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Quipt Home Medical has lower revenue, but higher earnings than Fulgent Genetics. Quipt Home Medical is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.
Fulgent Genetics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Quipt Home Medical has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
Summary
Fulgent Genetics beats Quipt Home Medical on 10 of the 19 factors compared between the two stocks.
Get Quipt Home Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for QIPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quipt Home Medical Competitors List
Related Companies and Tools
This page (NASDAQ:QIPT) was last updated on 2/22/2025 by MarketBeat.com Staff
